Market Analysis and Price Projections for HORIZANT ER
Introduction to HORIZANT ER
HORIZANT ER, also known as gabapentin enacarbil, is an extended-release formulation of gabapentin, a gamma-aminobutyric acid analog. It is primarily used for the management of postherpetic neuralgia (PHN) and restless legs syndrome (RLS)[2].
Current Market Pricing
As of the latest data, the cost for HORIZANT ER varies depending on the dosage and pharmacy.
- For a supply of 30 tablets of HORIZANT ER 300 mg, the price is approximately $553.
- Similarly, for HORIZANT ER 600 mg, the price is around $552.53 for 30 tablets[2].
The per-unit price for both dosages is roughly $18.42 per tablet.
Pricing Trends and Factors
Pharmaceutical Costs
The prices of HORIZANT ER tablets have remained relatively stable, with minor fluctuations. For instance, the price per unit for HORIZANT ER 300 mg and 600 mg tablets has been consistent, ranging from $16.47 to $16.49 per unit as of late 2024[1].
Patent Protection and Generic Entry
HORIZANT ER is currently protected by several patents, with the earliest generic entry date estimated to be June 10, 2029. This protection significantly influences the pricing, as generic versions are not yet available[4].
Sales and Revenue
HORIZANT ER generated significant revenue, with annual sales reaching $171 million in 2021 and a peak of $535 million in 2018. This indicates a strong market presence and demand for the drug[4].
Clinical Use and Demand
Indications
HORIZANT ER is approved for the treatment of PHN and RLS. Its efficacy in these conditions contributes to its market demand. Additionally, there have been clinical trials exploring its use in other conditions, such as alcohol use disorder, although these have shown mixed results[3].
Dosage Adjustments
The drug's dosage is adjusted based on renal function, which can affect its pricing and accessibility for patients with varying levels of kidney function[5].
Side Effects and Patient Compliance
Common Adverse Reactions
Common side effects include somnolence, dizziness, and fatigue. These side effects can impact patient compliance and, consequently, the drug's market performance. However, many of these symptoms resolve within a few weeks of treatment[5].
Market Projections
Patent Exclusivity
The patent protection until June 10, 2029, ensures that HORIZANT ER will remain a brand-name drug for several more years. This exclusivity is likely to maintain current pricing levels, as generic competition will not be introduced during this period[4].
Potential Generic Entry
Once the patents expire, generic versions of gabapentin enacarbil are expected to enter the market, which could significantly reduce the price of the drug. This transition is anticipated to increase accessibility but may also impact the revenue generated by the brand-name version.
Market Competition
While HORIZANT ER remains the only brand-name option for gabapentin enacarbil, its market share is secure. However, the introduction of generic alternatives will likely lead to increased competition and potentially lower prices.
Financial Projections
Revenue Impact
The entry of generic versions in 2029 is expected to reduce the revenue generated by HORIZANT ER. Historically, the introduction of generics can lead to a significant drop in sales for the brand-name drug, often by 50-70% or more.
Pricing Adjustments
In anticipation of generic competition, the manufacturer may adjust pricing strategies to maintain market share. This could include discounts, copay cards, or other patient assistance programs to keep patients on the brand-name drug.
Key Takeaways
- Current Pricing: HORIZANT ER costs around $553 for a 30-tablet supply of 300 mg or 600 mg tablets.
- Patent Protection: The drug remains protected by patents until June 10, 2029.
- Generic Entry: Generic versions are expected to enter the market in 2029, likely reducing prices and impacting revenue.
- Clinical Use: The drug is used for PHN and RLS, with dosage adjustments based on renal function.
- Side Effects: Common side effects include somnolence, dizziness, and fatigue, which can affect patient compliance.
FAQs
What is HORIZANT ER used for?
HORIZANT ER is used for the management of postherpetic neuralgia (PHN) and restless legs syndrome (RLS)[2].
How much does HORIZANT ER cost?
The cost for HORIZANT ER is approximately $553 for a supply of 30 tablets, depending on the pharmacy[2].
When will generic versions of HORIZANT ER be available?
Generic versions of HORIZANT ER are expected to be available starting June 10, 2029, when the current patents expire[4].
What are the common side effects of HORIZANT ER?
Common side effects include somnolence, dizziness, and fatigue. These symptoms often resolve within a few weeks of treatment[5].
How does renal function affect the dosage of HORIZANT ER?
The dosage of HORIZANT ER is adjusted based on the patient's creatinine clearance, which reflects renal function. Patients with lower creatinine clearance may require lower doses or less frequent dosing[5].
What impact will generic entry have on the price of HORIZANT ER?
The introduction of generic versions is expected to significantly reduce the price of HORIZANT ER, making it more accessible to patients but also reducing the revenue generated by the brand-name drug.
Sources
- DrugPatentWatch: Pharmaceutical drug prices and trends for HORIZANT.
- Drugs.com: Horizant Prices, Coupons, Copay Cards & Patient Assistance.
- National Institute on Alcohol Abuse and Alcoholism: Horizant Study Data Access.
- DrugPatentWatch: When will the patents on HORIZANT expire, and other related information.
- FDA: Horizant (gabapentin enacarbil extended-release tablets) NDA.
